A Phase 1/3 Study of FPA144 Combined With Modified FOLFOX6 Versus Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer (FIGHT)

Trial Profile

A Phase 1/3 Study of FPA144 Combined With Modified FOLFOX6 Versus Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer (FIGHT)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs FPA 144 (Primary)
  • Indications Gastric cancer; Gastrointestinal cancer
  • Focus Adverse reactions
  • Acronyms FIGHT
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 09 Nov 2017 Status changed from planning to not yet recruiting.
    • 15 Aug 2017 New trial record
    • 08 Aug 2017 According to a Five Prime Therapeutics media release, This safety trial will support the start of the global Phase 3 clinical trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top